Literature DB >> 21886664

A case of severe visceral leishmaniasis resulting from travel to Greece.

Alexander Hamilton1, Anthony Kelleher, Debbie Marriott.   

Abstract

Visceral leishmaniasis is rare in the developed world, particularly in immunocompetent hosts. It must be considered, however, in patients who are unwell, febrile and unresponsive to conventional antibiotics with a history of travel to areas where leishmaniasis is endemic. A case of more severe clinical manifestations than have been previously reported in Australia is presented here. The recent introduction of PCR technology for the detection of Leishmania in Australia has improved the diagnosis and management of leishmaniasis. Treatment with liposomal amphotericin B proved to be very effective in this severe case of visceral leishmaniasis.

Entities:  

Year:  2009        PMID: 21886664      PMCID: PMC3027726          DOI: 10.1136/bcr.06.2009.2036

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  11 in total

Review 1.  Advances in leishmaniasis.

Authors:  Henry W Murray; Jonathan D Berman; Clive R Davies; Nancy G Saravia
Journal:  Lancet       Date:  2005 Oct 29-Nov 4       Impact factor: 79.321

Review 2.  New world cutaneous leishmaniasis in travellers.

Authors:  Eli Schwartz; Cristoph Hatz; Johannes Blum
Journal:  Lancet Infect Dis       Date:  2006-06       Impact factor: 25.071

3.  An Australian case of New World cutaneous leishmaniasis.

Authors:  Pamela Konecny; Damien J Stark
Journal:  Med J Aust       Date:  2007-03-19       Impact factor: 7.738

4.  Visceral leishmaniasis and other severe infections in an adult patient with p47-phox-deficient chronic granulomatous disease.

Authors:  V Asensi; L Tricas; A Meana; D Roos; J A Carton; J A Maradona; M F Fresno; E Valle; J Fierer; J M Arribas
Journal:  Infection       Date:  2000 May-Jun       Impact factor: 3.553

5.  Mutational analysis of patients with p47-phox-deficient chronic granulomatous disease: The significance of recombination events between the p47-phox gene (NCF1) and its highly homologous pseudogenes.

Authors:  N Vázquez; T Lehrnbecher; R Chen; B L Christensen; J I Gallin; H Malech; S Holland; S Zhu; S J Chanock
Journal:  Exp Hematol       Date:  2001-02       Impact factor: 3.084

Review 6.  Leishmaniasis.

Authors:  B L Herwaldt
Journal:  Lancet       Date:  1999-10-02       Impact factor: 79.321

7.  Visceral leishmaniasis: a trip to the Greek Islands is not always idyllic.

Authors:  Oui Ju; David I Grove; Wilfrid J Jaksic; Geoffrey W Dart
Journal:  Med J Aust       Date:  2004-10-18       Impact factor: 7.738

Review 8.  Progress in the treatment of a neglected infectious disease: visceral leishmaniasis.

Authors:  Henry W Murray
Journal:  Expert Rev Anti Infect Ther       Date:  2004-04       Impact factor: 5.091

9.  Killing of intracellular Leishmania donovani by lymphokine-stimulated human mononuclear phagocytes. Evidence that interferon-gamma is the activating lymphokine.

Authors:  H W Murray; B Y Rubin; C D Rothermel
Journal:  J Clin Invest       Date:  1983-10       Impact factor: 14.808

10.  Chronic Granulomatous Disease; fundamental stages in our understanding of CGD.

Authors:  Tracy Assari
Journal:  Med Immunol       Date:  2006-09-21
View more
  1 in total

Review 1.  Non-Endemic Leishmaniases Reported Globally in Humans between 2000 and 2021-A Comprehensive Review.

Authors:  Rafael Rocha; André Pereira; Carla Maia
Journal:  Pathogens       Date:  2022-08-16
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.